title: [Prognosis and related factors of acute lymphoblastic leukemia].
abstract: In order to analyze the prognosis and related factors of acute lymphoblastic leukemia (ALL), 53 newly diagnosed ALL patients were enrolled in this study. The therapeutic efficacy and prognosis of 53 cases of ALL were analyzed, the remission, relapse, overall survival and event-free survival were studied, and relation between different factors and prognosis of ALL were investigated by comparison of cases in same stage. The results showed that the complete remission was achieved in 36 out of 53 patients, the total remission rate was 67.9%, the total relapse rate was 37.7%, the median relapse duration was 6 months after remission. Median overall survival (OS) and median event-free survival (EFS) time were 4 and 1 months after remission respectively, OS and EFS rate of 18 month was 35.1% and 14.2%. The patients with different gender had significantly different EFS. Age was an independent risk factor of CR rate. White blood cell count and hemoglobin level of newly diagnosed patients were significantly correlated with OS and EFS. Absolute neutrophil count (ANC) at the end of the induction chemotherapy was an independent related factor of OS, the higher ANC, the lower risk of death. The patients with or without chemotherapy related infection had different relapse rate. The patients with bleeding after chemotherapy had lower OS when compared with those without bleeding. Serum glucose level was a significant negative prognostic factor. It is concluded that there is higher relapse rate, poor prognosis in adult ALL in comparison with children. In order to decrease the relapse rate and prolong the EFS, individual therapeutical regimens and prophylaxis of complicating diseases should be applied to ALL patients.
authors.affiliation: Department of Hematology and Oncology, General Hospital, Tianjin Medical University, Tianjin 300052, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Liu
authors.forename: Yu-Qian
authors.initials: YQ
authors.lastname: Cheng
authors.forename: Wen-Xiu
authors.initials: WX
authors.lastname: Song
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: DU
authors.forename: Er-Bao
authors.initials: EB
authors.lastname: Ruan
authors.forename: Li-Tong
authors.initials: LT
authors.lastname: Zhang
authors.forename: Xiao-Ming
authors.initials: XM
authors.lastname: Wang
authors.forename: Yong
authors.initials: Y
authors.lastname: Liang
authors.forename: Guo-Jin
authors.initials: GJ
authors.lastname: Wang
authors.forename: Wen
authors.initials: W
authors.lastname: Qu
authors.forename: Jia
authors.initials: J
authors.lastname: Song
authors.forename: Rong-Li
authors.initials: RL
authors.lastname: Zhang
authors.forename: Jing
authors.initials: J
authors.lastname: Guan
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Li
authors.forename: Peng
authors.initials: P
authors.lastname: Zou
authors.forename: Zong-Hong
authors.initials: ZH
authors.lastname: Shao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D055815:Young Adult